PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
31700015-7	2019	Relative to control, dietary supplementation with des-fluoro-anacetrapib reduced plasma CETP activity by 89 +- 6.9%, increased plasma apolipoprotein A-I levels by 24 +- 5.5%, increased plasma HDL-C levels by 93 +- 26% and reduced intimal hyperplasia in the grafted vein by 38 +- 6.2%.	des-fluoro-anacetrapib	50-72	apolipoprotein A-I	Oryctolagus cuniculus	134-152	
26204569-6	2015	Treatment with 0.07% and 0.14% (wt/wt) des-fluoro-anacetrapib reduced CETP activity by 63+-12% and 81+-8.6%, increased plasma apoA-I levels by 1.3+-0.1- and 1.4+-0.1-fold, and increased plasma HDL-cholesterol levels by 1.4+-0.1- and 1.7+-0.2-fold, respectively.	des-fluoro-anacetrapib	39-61	apolipoprotein A-I	Oryctolagus cuniculus	126-132